Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 210.00K | 2.47B | 512.50K | 0.00 |
Gross Profit | -9.00K | -37.00K | 49.00K | 2.47B | 127.50K | -90.16K |
EBITDA | -11.97M | -12.66M | -10.96M | -13.73M | -13.08M | -10.00M |
Net Income | -8.86M | -12.55M | -9.81M | -13.49M | -12.95M | -10.13M |
Balance Sheet | ||||||
Total Assets | 17.65M | 21.59M | 25.52M | 30.41M | 36.26M | 9.45M |
Cash, Cash Equivalents and Short-Term Investments | 16.03M | 19.92M | 23.84M | 29.69M | 35.73M | 9.06M |
Total Debt | 213.00K | 232.00K | 175.00K | 221.00K | 259.48K | 55.20K |
Total Liabilities | 2.24M | 2.70M | 2.15M | 2.21M | 1.49M | 1.19M |
Stockholders Equity | 16.59M | 20.00M | 24.34M | 29.05M | 35.44M | 8.76M |
Cash Flow | ||||||
Free Cash Flow | -6.84M | -7.33M | -6.21M | -6.49M | -4.94M | -6.19M |
Operating Cash Flow | -6.84M | -7.33M | -6.21M | -6.49M | -4.94M | -6.18M |
Investing Cash Flow | 5.08M | 4.28M | -5.60M | -10.73M | -3.92M | -305.79K |
Financing Cash Flow | 2.04M | 3.42M | 366.00K | 452.00K | 31.57M | 9.41M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | $110.27M | ― | -57.94% | ― | ― | 11.78% | |
44 Neutral | 580.99M | -2.69 | 0.00% | ― | -78.63% | 1.88% | |
42 Neutral | 16.57M | -0.48 | 0.00% | ― | 77.78% | 84.08% | |
39 Underperform | 6.91M | -0.10 | 246.96% | ― | -39.80% | 56.07% | |
38 Underperform | 10.28M | -0.02 | 0.00% | 3.27% | -87.50% | 92.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Anixa Biosciences, in collaboration with Cleveland Clinic, unveiled promising results from their Phase 1 trial of a breast cancer vaccine aimed at triple-negative breast cancer (TNBC). The vaccine, based on groundbreaking research, showed safety and efficacy in activating immune responses in patients. As they gear up for a Phase 2 study in 2025, the vaccine’s potential to become a preventive measure against aggressive breast cancer offers hope for future treatments and partnerships with major pharmaceutical firms.